Robert C. Bast

76.6k total citations · 15 hit papers
608 papers, 44.8k citations indexed

About

Robert C. Bast is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Robert C. Bast has authored 608 papers receiving a total of 44.8k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Molecular Biology, 195 papers in Reproductive Medicine and 182 papers in Oncology. Recurrent topics in Robert C. Bast's work include Ovarian cancer diagnosis and treatment (193 papers), Monoclonal and Polyclonal Antibodies Research (91 papers) and HER2/EGFR in Cancer Research (49 papers). Robert C. Bast is often cited by papers focused on Ovarian cancer diagnosis and treatment (193 papers), Monoclonal and Polyclonal Antibodies Research (91 papers) and HER2/EGFR in Cancer Research (49 papers). Robert C. Bast collaborates with scholars based in United States, United Kingdom and China. Robert C. Bast's co-authors include Gordon B. Mills, Robert C. Knapp, Ian Jacobs, Andrew Berchuck, Daniel F. Hayes, Jonathan M. Niloff, Mark R. Somerfield, Bryan T. Hennessy, Robert Mennel and Robert B. Colvin and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Robert C. Bast

599 papers receiving 43.3k citations

Hit Papers

A Radioimmunoassay Using a Monoclonal Antibody to Monitor... 1981 2026 1996 2011 1983 2007 1981 2006 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
    1983 1.7k citations Robert C. Bast et al. profile →
  2. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
    2007 1.7k citations Lyndsay N. Harris, Robert Mennel et al. Journal of Clinical Oncology profile →
  3. Reactivity of a monoclonal antibody with human ovarian carcinoma.
    1981 1.3k citations Robert C. Bast et al. profile →
  4. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
    2006 1.2k citations Daniel F. Hayes, Robert C. Bast et al. Journal of Clinical Oncology profile →
  5. The biology of ovarian cancer: new opportunities for translation
    2009 1.1k citations Robert C. Bast, Gordon B. Mills et al. profile →
  6. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer
    2004 741 citations Robert C. Bast, Yinhua Yu et al. Cancer Research profile →
  7. The CA 125 tumour-associated antigen: a review of the literature
    1989 729 citations Ian Jacobs, Robert C. Bast profile →
  8. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
    2000 688 citations Yiling Lu, Robert C. Bast et al. profile →
  9. 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
    2001 660 citations Robert C. Bast, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
  10. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    2008 641 citations Robert C. Bast, Steven J. Skates et al. Gynecologic Oncology profile →
  11. Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation
    1988 599 citations Robert C. Bast et al. profile →
  12. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    2016 576 citations Lyndsay N. Harris, Nofisat Ismaila et al. Journal of Clinical Oncology profile →
  13. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
    1996 553 citations Robert C. Bast, Robert Mennel et al. profile →
  14. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    2007 532 citations Steven J. Skates, Robert C. Bast et al. Gynecologic Oncology profile →
  15. Tissue Distribution of a Coelomic- Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125
    1983 485 citations Robert C. Bast et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert C. Bast United States 105 17.8k 13.7k 13.7k 9.6k 6.9k 608 44.8k
Giovanni Scambia Italy 89 11.1k 0.6× 16.5k 1.2× 12.4k 0.9× 4.3k 0.4× 4.2k 0.6× 2.0k 49.2k
Martin Gore United Kingdom 78 12.9k 0.7× 4.9k 0.4× 14.4k 1.0× 4.9k 0.5× 3.6k 0.5× 382 29.5k
Ignace Vergote Belgium 89 7.3k 0.4× 21.6k 1.6× 13.5k 1.0× 5.2k 0.5× 2.6k 0.4× 899 38.3k
Elizabeth A. Eisenhauer Canada 61 12.0k 0.7× 2.9k 0.2× 15.2k 1.1× 7.3k 0.8× 3.2k 0.5× 213 41.9k
Elisabeth G.E. de Vries Netherlands 102 14.3k 0.8× 2.2k 0.2× 24.1k 1.8× 6.4k 0.7× 4.3k 0.6× 1.0k 47.8k
Ursula A. Matulonis United States 77 7.9k 0.4× 8.2k 0.6× 13.4k 1.0× 3.1k 0.3× 3.3k 0.5× 443 23.1k
Robert L. Coleman United States 72 7.7k 0.4× 9.5k 0.7× 7.7k 0.6× 3.5k 0.4× 1.7k 0.3× 690 23.3k
Michael Friedländer Australia 73 7.5k 0.4× 9.8k 0.7× 15.7k 1.1× 4.6k 0.5× 1.6k 0.2× 493 27.5k
Andrew Berchuck United States 73 8.1k 0.5× 6.9k 0.5× 5.8k 0.4× 3.8k 0.4× 1.7k 0.2× 358 19.9k
Amit M. Oza Canada 72 7.4k 0.4× 7.0k 0.5× 10.8k 0.8× 3.5k 0.4× 1.7k 0.2× 599 21.7k

Countries citing papers authored by Robert C. Bast

Since Specialization
Citations

This map shows the geographic impact of Robert C. Bast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Bast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Bast more than expected).

Fields of papers citing papers by Robert C. Bast

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Bast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Bast. The network helps show where Robert C. Bast may publish in the future.

Co-authorship network of co-authors of Robert C. Bast

This figure shows the co-authorship network connecting the top 25 collaborators of Robert C. Bast. A scholar is included among the top collaborators of Robert C. Bast based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert C. Bast. Robert C. Bast is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Fang, Xuejiao Yu, Jun Qian, et al.. (2024). A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resistance Updates. 74. 101077–101077. 7 indexed citations
2.
Kobayashi, Makoto, Hiroyuki Katayama, Ehsan Irajizad, et al.. (2020). Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers. 12(2). 485–485. 7 indexed citations
3.
4.
Gentry‐Maharaj, Aleksandra, Oleg Blyuss, Andy Ryan, et al.. (2020). Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers. 12(7). 1931–1931. 22 indexed citations
5.
Fourkala, Evangelia Ourania, Aleksandra Gentry‐Maharaj, Andy Ryan, et al.. (2019). Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research. 12(6). 391–400. 22 indexed citations
6.
Yang, Wei-Lei, Aleksandra Gentry‐Maharaj, Andy Ryan, et al.. (2017). Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research. 23(19). 5912–5922. 44 indexed citations
7.
Harris, Lyndsay N., Nofisat Ismaila, Lisa M. McShane, et al.. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 34(10). 1134–1150. 576 indexed citations breakdown →
8.
Zhou, Jinhua, Shu Zhang, Abdulkhaliq Alsaadi, et al.. (2016). A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research. 23(8). 1945–1954. 48 indexed citations
9.
Zhang, Shu, Zhen Lü, Anna K. Unruh, et al.. (2014). Clinically Relevant microRNAs in Ovarian Cancer. Molecular Cancer Research. 13(3). 393–401. 70 indexed citations
10.
Su, Jen-Liang, Xiaoyun Cheng, Hirohito Yamaguchi, et al.. (2011). FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research. 71(21). 6878–6887. 39 indexed citations
11.
Ahmed, Ahmed A., Xiaoyan Wang, Zhen Lü, et al.. (2011). Modulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to Paclitaxel. Cancer Research. 71(17). 5806–5817. 45 indexed citations
12.
13.
14.
Le, Xiao-Feng, et al.. (2004). HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell Cycle. 4(1). 87–95. 114 indexed citations
15.
Le, Xiao‐Feng, David Gold, Yiling Lu, et al.. (2004). Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. Journal of Biological Chemistry. 280(3). 2092–2104. 58 indexed citations
16.
Xiao, Le, Amanda McWatters, Jon R. Wiener, et al.. (2000). Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.. PubMed. 6(1). 260–70. 50 indexed citations
17.
Boyer, Cinda M., Lajos Pusztai, Jon R. Wiener, et al.. (1999). Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. International Journal of Cancer. 82(4). 525–531. 21 indexed citations
18.
Boente, Matthew, Andrew Berchuck, Regina S. Whitaker, et al.. (1998). Suppression of Diacylglycerol Levels by Antibodies Reactive with the c-erbB-2 (HER-2/neu) Gene Product p185c-erbB-2in Breast and Ovarian Cancer Cell Lines. Gynecologic Oncology. 70(1). 49–55. 4 indexed citations
19.
Boyer, C., Russel E. Kaufman, Kathy O'Briant, et al.. (1991). Expression and amplification of the HER-2/ neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. American Journal of Obstetrics and Gynecology. 165(3). 640–646. 57 indexed citations
20.
Carreño, V., et al.. (1988). Prevalencia de hepatitis por virus A, B y D en niños. Anales de Pediatría. 29(5). 357–362. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giovanni Scambia Breakdown of academic impact, for papers by Martin Gore Breakdown of academic impact, for papers by Ignace Vergote Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by Ursula A. Matulonis Breakdown of academic impact, for papers by Robert L. Coleman Breakdown of academic impact, for papers by Michael Friedländer Breakdown of academic impact, for papers by Andrew Berchuck Breakdown of academic impact, for papers by Amit M. Oza
Rankless by CCL
2026